Elige tu región

Selecciona la región que mejor se ajuste a tu ubicación o preferencias.

International

Elige el idioma del sitio

Esta configuración controla el idioma de la interfaz de usuario, incluidos los botones, los menús y todo el texto del sitio. Selecciona tu idioma preferido para la mejor experiencia de navegación.

Elige los idiomas para los anuncios de empleo

Selecciona los idiomas para los anuncios de empleo que deseas ver. Esta configuración determina qué anuncios de empleo se mostrarán.

Pieris Pharmaceuticals GmbH

Frisinga, Alemania

Suscribirse a nuevos puestos de trabajo

Visitar página Web

Sobre el empleador

Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin^® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.

Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.

Pieris has a diverse pipeline of Anticalin Therapeutics for a number of different indications and has active, multi-program R&D collaborations with Roche, Daiichi Sankyo, the Sanofi Group, Zydus Cadila and Stelis Biopharma.

Pieris, founded in 2001, was funded by premier biotechnology-focused venture capital firms including OrbiMed Advisors as its lead investor as well as Forbion Capital, Gilde Healthcare Partners, Novo Nordisk Ventures, Global Life Science Ventures, BayTech Venture Capital, Bio-M, TCB, KfW and BayernKapital.

Pieris has become a publicly traded company on December 18, 2014 (NASDAQ:PIRS).